This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
3D Atopic Dermatitis Model
Disease specific in vitro models for your research
Skimune® AD
Our advanced Skimune® model stimulated to demonstrate an AD phenotype through addition of inflammatory cytokines and autologous immune cells.
Skimune® Epi AD
Based on our Skimune® Epi platform, Skimune® Epi AD exhibits key phenotypical markers of AD in a 96 well plate high throughput format, perfect for larger scale screening requirements.
Custom disease model optimisation, contact us for more information
Get in touchOur advanced Skimune® model stimulated to demonstrate an AD phenotype through addition of inflammatory cytokines and autologous immune cells.
Skimune® Epi AD
Based on our Skimune® Epi platform, Skimune® Epi AD exhibits key phenotypical markers of AD in a 96 well plate high throughput format, perfect for larger scale screening requirements.
Custom disease model optimisation, contact us for more information
At a glance
Skimune® AD decreased Filaggrin and increased TSLP expression, typical in Atopic Dermatitis.
Addition of steroids are able to reverse this response.
Uses
Testing efficacy of novel drug compounds.
Mechanistic assessment of immune cell responses to both AD onset and therapies.
Skimune® AD
Benefits of Skimune® AD are:
Real human tissues represent the complexity of in vivo biology
Induced through validated cytokine cocktails and autologous PBMCs to mimic typical Atopic dermatitis responses
Does not rely on patient derived samples
Reduces variability caused by pre-existing treatment regimes
Validated for mechanistic assessment of steroid formulations and monoclonal antibodies
Get in touchSkimune® AD is a human explant model which is induced to express an Atopic Dermatitis phenotype through co-culture with autologous immune cells and an inflammatory cytokine cocktail.
Markers for AD phenotypes such as Filaggrin and Thymic Stromal Lyphoprotein (TSLP) are lowered and raised respectively in Skimune® AD similarly to that observed in clinical patient samples (Figure 1). These biomarkers can be detected by immunohistochemistry and quantified in supernatants using ELISA to demonstrate significant differences between stimulated tissues and unstimulated controls (Figure 2). Application of standard AD therapeutics such as hydrocortisone was able to reverse the AD induced phenotype (Figure 1). Skimune® AD is a powerful tool for AD research.
Markers for AD phenotypes such as Filaggrin and Thymic Stromal Lyphoprotein (TSLP) are lowered and raised respectively in Skimune® AD similarly to that observed in clinical patient samples (Figure 1). These biomarkers can be detected by immunohistochemistry and quantified in supernatants using ELISA to demonstrate significant differences between stimulated tissues and unstimulated controls (Figure 2). Application of standard AD therapeutics such as hydrocortisone was able to reverse the AD induced phenotype (Figure 1). Skimune® AD is a powerful tool for AD research.
Figure 1 - H&E and immunostaining for TSLP in control, AD induced, 1% Hydrocortisone treated, and 0.05% Clobetasol Propionate treated conditions. TSLP staining is dramatically reduced in treated samples.
Figure 2 - ELISA analysis of supernatant Filaggrin and TSLP shows disease specific changes in AD induced models.
Skimune® Epi AD
Benefits of Skimune® Epi AD are:
Cytokine induced epidermal model allows for high throughput assessment of disease modifying treatments
Get in touchAlcyomics is also in the process of developing an epidermal Atopic Dermatitis model for high throughput screening needs (Figure 1).
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Based on Skimune® Epi, this model allows for the screening of 100s of compounds/ drugs simultaneously, significantly increasing the throughput compared to other commercially available models.
Figure 1 - Skimmune® Epi AD
Figure 2 - TMSP and Filaggrin immunofluorescence staining increased and decreased in AD induction.
